ID   CDK13_HUMAN             Reviewed;        1512 AA.
AC   Q14004; Q53G78; Q6DKQ9; Q75MH4; Q75MH5; Q96JN4; Q9H4A0; Q9H4A1;
AC   Q9UDR4;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   10-MAY-2005, sequence version 2.
DT   10-MAY-2017, entry version 173.
DE   RecName: Full=Cyclin-dependent kinase 13;
DE            EC=2.7.11.22;
DE            EC=2.7.11.23;
DE   AltName: Full=CDC2-related protein kinase 5;
DE   AltName: Full=Cell division cycle 2-like protein kinase 5;
DE   AltName: Full=Cell division protein kinase 13;
DE            Short=hCDK13;
DE   AltName: Full=Cholinesterase-related cell division controller;
GN   Name=CDK13; Synonyms=CDC2L, CDC2L5, CHED, KIAA1791;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND VARIANTS LEU-700
RP   AND MET-1170.
RC   TISSUE=Placenta;
RX   PubMed=11162436; DOI=10.1006/bbrc.2000.4042;
RA   Marques F., Moreau J.L., Peaucellier G., Lozano J.C., Schatt P.,
RA   Picard A., Callebaut I., Perre E., Geneviere A.M.;
RT   "A new subfamily of high molecular mass CDC2-related kinases with
RT   PITAI/VRE.";
RL   Biochem. Biophys. Res. Commun. 279:832-837(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ALA-356; PHE-403;
RP   GLN-410; ALA-500; GLY-624 AND MET-1062.
RG   NIEHS SNPs program;
RL   Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 361-1078, FUNCTION, AND VARIANT LEU-700.
RC   TISSUE=Glioblastoma;
RX   PubMed=1731328; DOI=10.1073/pnas.89.2.579;
RA   Lapidot-Lifson Y., Patinkin D., Prody C.A., Ehrlich G., Seidman S.,
RA   Ben-Aziz R., Benseler F., Eckstein F., Zakut H., Soreq H.;
RT   "Cloning and antisense oligodeoxynucleotide inhibition of a human
RT   homolog of cdc2 required in hematopoiesis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:579-583(1992).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 856-1512 (ISOFORM 2).
RC   TISSUE=Thyroid;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 860-1512 (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=11347906; DOI=10.1093/dnares/8.2.85;
RA   Nagase T., Nakayama M., Nakajima D., Kikuno R., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XX.
RT   The complete sequences of 100 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 8:85-95(2001).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=15144186; DOI=10.1021/ac035352d;
RA   Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,
RA   Peters E.C.;
RT   "Robust phosphoproteomic profiling of tyrosine phosphorylation sites
RT   from human T cells using immobilized metal affinity chromatography and
RT   tandem mass spectrometry.";
RL   Anal. Chem. 76:2763-2772(2004).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-1246, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [9]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH C1QBP.
RX   PubMed=16721827; DOI=10.1002/jcb.20986;
RA   Even Y., Durieux S., Escande M.L., Lozano J.C., Peaucellier G.,
RA   Weil D., Geneviere A.M.;
RT   "CDC2L5, a Cdk-like kinase with RS domain, interacts with the ASF/SF2-
RT   associated protein p32 and affects splicing in vivo.";
RL   J. Cell. Biochem. 99:890-904(2006).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH HIV-1 TAT.
RX   PubMed=18480452; DOI=10.1128/JVI.02543-07;
RA   Berro R., Pedati C., Kehn-Hall K., Wu W., Klase Z., Even Y.,
RA   Geneviere A.M., Ammosova T., Nekhai S., Kashanchi F.;
RT   "CDK13, a new potential human immunodeficiency virus type 1 inhibitory
RT   factor regulating viral mRNA splicing.";
RL   J. Virol. 82:7155-7166(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-1246, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-315; SER-317; SER-325;
RP   SER-340; SER-342; SER-383; SER-395; SER-397; SER-400; SER-437; SER-439
RP   AND THR-871, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1048, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [18]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-556, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [19]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=20952539; DOI=10.1101/gad.1968210;
RA   Bartkowiak B., Liu P., Phatnani H.P., Fuda N.J., Cooper J.J.,
RA   Price D.H., Adelman K., Lis J.T., Greenleaf A.L.;
RT   "CDK12 is a transcription elongation-associated CTD kinase, the
RT   metazoan ortholog of yeast Ctk1.";
RL   Genes Dev. 24:2303-2316(2010).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-383; SER-437; SER-439;
RP   SER-525 AND THR-871, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [22]
RP   RNA EDITING OF POSITION 103.
RX   PubMed=21835166; DOI=10.1016/j.bbrc.2011.07.075;
RA   Maas S., Godfried Sie C.P., Stoev I., Dupuis D.E., Latona J.,
RA   Porman A.M., Evans B., Rekawek P., Kluempers V., Mutter M.,
RA   Gommans W.M., Lopresti D.;
RT   "Genome-wide evaluation and discovery of vertebrate A-to-I RNA editing
RT   sites.";
RL   Biochem. Biophys. Res. Commun. 412:407-412(2011).
RN   [23]
RP   INTERACTION WITH CCNK.
RX   PubMed=22012619; DOI=10.1101/gad.16962311;
RA   Blazek D., Kohoutek J., Bartholomeeusen K., Johansen E., Hulinkova P.,
RA   Luo Z., Cimermancic P., Ule J., Peterlin B.M.;
RT   "The Cyclin K/Cdk12 complex maintains genomic stability via regulation
RT   of expression of DNA damage response genes.";
RL   Genes Dev. 25:2158-2172(2011).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-315; SER-317; SER-383;
RP   SER-395; SER-397; SER-400; SER-437; SER-439; THR-871 AND THR-1246, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-315; SER-317; SER-325;
RP   SER-358; SER-360; SER-383; SER-437; SER-439; SER-525; THR-588;
RP   THR-871; SER-1048 AND THR-1246, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [27]
RP   VARIANTS [LARGE SCALE ANALYSIS] ALA-494; ALA-500; ARG-670 AND
RP   MET-1170.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Cyclin-dependent kinase which displays CTD kinase
CC       activity and is required for RNA splicing. Has CTD kinase activity
CC       by hyperphosphorylating the C-terminal heptapeptide repeat domain
CC       (CTD) of the largest RNA polymerase II subunit RPB1, thereby
CC       acting as a key regulator of transcription elongation. Required
CC       for RNA splicing, probably by phosphorylating SRSF1/SF2. Required
CC       during hematopoiesis. In case of infection by HIV-1 virus,
CC       interacts with HIV-1 Tat protein acetylated at 'Lys-50' and 'Lys-
CC       51', thereby increasing HIV-1 mRNA splicing and promoting the
CC       production of the doubly spliced HIV-1 protein Nef.
CC       {ECO:0000269|PubMed:16721827, ECO:0000269|PubMed:1731328,
CC       ECO:0000269|PubMed:18480452, ECO:0000269|PubMed:20952539}.
CC   -!- CATALYTIC ACTIVITY: ATP + [DNA-directed RNA polymerase] = ADP +
CC       [DNA-directed RNA polymerase] phosphate.
CC       {ECO:0000269|PubMed:20952539}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:20952539}.
CC   -!- SUBUNIT: Interacts with CCNL1 and CCNL2 (By similarity). Interacts
CC       with CCNK. Interacts with C1QBP. Interacts with HIV-1 Tat.
CC       {ECO:0000250, ECO:0000269|PubMed:16721827,
CC       ECO:0000269|PubMed:18480452, ECO:0000269|PubMed:22012619}.
CC   -!- INTERACTION:
CC       Q07021:C1QBP; NbExp=6; IntAct=EBI-6375898, EBI-347528;
CC       O75909:CCNK; NbExp=6; IntAct=EBI-968626, EBI-739806;
CC   -!- SUBCELLULAR LOCATION: Nucleus speckle
CC       {ECO:0000269|PubMed:16721827}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q14004-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q14004-2; Sequence=VSP_013579;
CC   -!- TISSUE SPECIFICITY: Expressed in fetal brain, liver, muscle and in
CC       adult brain. Also expressed in neuroblastoma and glioblastoma
CC       tumors.
CC   -!- RNA EDITING: Modified_positions=103 {ECO:0000269|PubMed:21835166};
CC       Note=Edited at about 88%.;
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC
CC       Ser/Thr protein kinase family. CDC2/CDKX subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA58424.1; Type=Frameshift; Positions=1006; Evidence={ECO:0000305};
CC       Sequence=AAS07490.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/cdc2l5/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ297709; CAC10400.1; -; mRNA.
DR   EMBL; AJ297710; CAC10401.1; -; mRNA.
DR   EMBL; AY679523; AAT74623.1; -; Genomic_DNA.
DR   EMBL; AC072061; AAS07490.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AC072061; AAS07491.1; -; Genomic_DNA.
DR   EMBL; AC006023; AAD54514.1; -; Genomic_DNA.
DR   EMBL; M80629; AAA58424.1; ALT_FRAME; mRNA.
DR   EMBL; AK223053; BAD96773.1; -; mRNA.
DR   EMBL; AB058694; BAB47420.1; -; mRNA.
DR   CCDS; CCDS5461.1; -. [Q14004-1]
DR   CCDS; CCDS5462.1; -. [Q14004-2]
DR   PIR; A38197; A38197.
DR   RefSeq; NP_003709.3; NM_003718.4. [Q14004-1]
DR   RefSeq; NP_112557.2; NM_031267.3. [Q14004-2]
DR   UniGene; Hs.233552; -.
DR   PDB; 5EFQ; X-ray; 2.00 A; A/C=694-1039.
DR   PDBsum; 5EFQ; -.
DR   ProteinModelPortal; Q14004; -.
DR   SMR; Q14004; -.
DR   BioGrid; 114176; 57.
DR   IntAct; Q14004; 15.
DR   MINT; MINT-1197921; -.
DR   STRING; 9606.ENSP00000181839; -.
DR   BindingDB; Q14004; -.
DR   ChEMBL; CHEMBL1795192; -.
DR   GuidetoPHARMACOLOGY; 1966; -.
DR   iPTMnet; Q14004; -.
DR   PhosphoSitePlus; Q14004; -.
DR   BioMuta; CDK13; -.
DR   DMDM; 66774048; -.
DR   EPD; Q14004; -.
DR   MaxQB; Q14004; -.
DR   PaxDb; Q14004; -.
DR   PeptideAtlas; Q14004; -.
DR   PRIDE; Q14004; -.
DR   DNASU; 8621; -.
DR   Ensembl; ENST00000181839; ENSP00000181839; ENSG00000065883. [Q14004-1]
DR   Ensembl; ENST00000340829; ENSP00000340557; ENSG00000065883. [Q14004-2]
DR   GeneID; 8621; -.
DR   KEGG; hsa:8621; -.
DR   UCSC; uc003thh.5; human. [Q14004-1]
DR   CTD; 8621; -.
DR   DisGeNET; 8621; -.
DR   GeneCards; CDK13; -.
DR   HGNC; HGNC:1733; CDK13.
DR   HPA; HPA059241; -.
DR   MIM; 603309; gene.
DR   neXtProt; NX_Q14004; -.
DR   OpenTargets; ENSG00000065883; -.
DR   PharmGKB; PA26264; -.
DR   eggNOG; KOG0600; Eukaryota.
DR   eggNOG; ENOG410XPIR; LUCA.
DR   GeneTree; ENSGT00860000133755; -.
DR   HOVERGEN; HBG050851; -.
DR   InParanoid; Q14004; -.
DR   KO; K08819; -.
DR   OMA; NVAPVKT; -.
DR   OrthoDB; EOG091G08Z8; -.
DR   PhylomeDB; Q14004; -.
DR   TreeFam; TF101060; -.
DR   Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SignaLink; Q14004; -.
DR   SIGNOR; Q14004; -.
DR   ChiTaRS; CDK13; human.
DR   GeneWiki; CDC2L5; -.
DR   GenomeRNAi; 8621; -.
DR   PMAP-CutDB; Q14004; -.
DR   PRO; PR:Q14004; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; ENSG00000065883; -.
DR   CleanEx; HS_CDC2L5; -.
DR   ExpressionAtlas; Q14004; baseline and differential.
DR   Genevisible; Q14004; HS.
DR   GO; GO:0005694; C:chromosome; IBA:GO_Central.
DR   GO; GO:0002945; C:cyclin K-CDK13 complex; IPI:MGI.
DR   GO; GO:0008024; C:cyclin/CDK positive transcription elongation factor complex; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0019908; C:nuclear cyclin-dependent protein kinase holoenzyme complex; ISS:UniProtKB.
DR   GO; GO:0016607; C:nuclear speck; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0030332; F:cyclin binding; IPI:MGI.
DR   GO; GO:0004693; F:cyclin-dependent protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0019901; F:protein kinase binding; IEA:Ensembl.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0008353; F:RNA polymerase II carboxy-terminal domain kinase activity; IDA:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IBA:GO_Central.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IBA:GO_Central.
DR   GO; GO:0000380; P:alternative mRNA splicing, via spliceosome; ISS:UniProtKB.
DR   GO; GO:0030097; P:hemopoiesis; IMP:UniProtKB.
DR   GO; GO:0007275; P:multicellular organism development; TAS:ProtInc.
DR   GO; GO:2000737; P:negative regulation of stem cell differentiation; IEA:Ensembl.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0070816; P:phosphorylation of RNA polymerase II C-terminal domain; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; TAS:ProtInc.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IBA:GO_Central.
DR   GO; GO:0007088; P:regulation of mitotic nuclear division; TAS:ProtInc.
DR   GO; GO:0006368; P:transcription elongation from RNA polymerase II promoter; IBA:GO_Central.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Complete proteome; Host-virus interaction; Kinase; mRNA processing;
KW   mRNA splicing; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; RNA editing;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN         1   1512       Cyclin-dependent kinase 13.
FT                                /FTId=PRO_0000085711.
FT   DOMAIN      705    998       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     711    719       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    837    837       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     734    734       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     315    315       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     317    317       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     325    325       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     340    340       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     342    342       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     358    358       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     360    360       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     383    383       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     395    395       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:21406692}.
FT   MOD_RES     397    397       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:21406692}.
FT   MOD_RES     400    400       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:21406692}.
FT   MOD_RES     437    437       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     439    439       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     525    525       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     556    556       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     588    588       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     871    871       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1048   1048       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1058   1058       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q69ZA1}.
FT   MOD_RES    1246   1246       Phosphothreonine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ    1079   1138       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:11162436,
FT                                ECO:0000303|Ref.5}.
FT                                /FTId=VSP_013579.
FT   VARIANT     103    103       Q -> R (in RNA edited version).
FT                                /FTId=VAR_066526.
FT   VARIANT     340    340       S -> F (in dbSNP:rs13622).
FT                                /FTId=VAR_053926.
FT   VARIANT     356    356       P -> A (in dbSNP:rs17537669).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_022381.
FT   VARIANT     403    403       L -> F (in dbSNP:rs3735137).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_022382.
FT   VARIANT     410    410       R -> Q (in dbSNP:rs17496261).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_022383.
FT   VARIANT     494    494       T -> A (in dbSNP:rs34624759).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041965.
FT   VARIANT     500    500       T -> A (in dbSNP:rs3735135).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_022384.
FT   VARIANT     624    624       S -> G (in dbSNP:rs17496275).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_022385.
FT   VARIANT     670    670       T -> R (in dbSNP:rs34775357).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041966.
FT   VARIANT     700    700       R -> L (in dbSNP:rs1057000).
FT                                {ECO:0000269|PubMed:11162436,
FT                                ECO:0000269|PubMed:1731328}.
FT                                /FTId=VAR_022386.
FT   VARIANT    1062   1062       V -> M (in dbSNP:rs17496712).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_022387.
FT   VARIANT    1170   1170       V -> M (in dbSNP:rs3204309).
FT                                {ECO:0000269|PubMed:11162436,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041967.
FT   CONFLICT     21     21       K -> R (in Ref. 1; CAC10400/CAC10401).
FT                                {ECO:0000305}.
FT   CONFLICT    671    671       A -> T (in Ref. 1; CAC10400/CAC10401 and
FT                                4; AAA58424). {ECO:0000305}.
FT   CONFLICT    810    810       N -> Y (in Ref. 4; AAA58424).
FT                                {ECO:0000305}.
FT   CONFLICT    862    866       YSSEE -> FSVFF (in Ref. 5; BAB47420).
FT                                {ECO:0000305}.
FT   CONFLICT   1180   1180       Q -> R (in Ref. 5; BAD96773).
FT                                {ECO:0000305}.
FT   CONFLICT   1356   1356       G -> E (in Ref. 5; BAD96773).
FT                                {ECO:0000305}.
FT   HELIX       702    704       {ECO:0000244|PDB:5EFQ}.
FT   STRAND      705    713       {ECO:0000244|PDB:5EFQ}.
FT   STRAND      715    724       {ECO:0000244|PDB:5EFQ}.
FT   TURN        725    727       {ECO:0000244|PDB:5EFQ}.
FT   STRAND      730    736       {ECO:0000244|PDB:5EFQ}.
FT   STRAND      739    741       {ECO:0000244|PDB:5EFQ}.
FT   HELIX       747    758       {ECO:0000244|PDB:5EFQ}.
FT   STRAND      767    772       {ECO:0000244|PDB:5EFQ}.
FT   STRAND      787    792       {ECO:0000244|PDB:5EFQ}.
FT   STRAND      795    797       {ECO:0000244|PDB:5EFQ}.
FT   HELIX       798    804       {ECO:0000244|PDB:5EFQ}.
FT   HELIX       811    830       {ECO:0000244|PDB:5EFQ}.
FT   HELIX       840    842       {ECO:0000244|PDB:5EFQ}.
FT   STRAND      843    845       {ECO:0000244|PDB:5EFQ}.
FT   STRAND      851    853       {ECO:0000244|PDB:5EFQ}.
FT   HELIX       856    858       {ECO:0000244|PDB:5EFQ}.
FT   STRAND      864    866       {ECO:0000244|PDB:5EFQ}.
FT   HELIX       877    879       {ECO:0000244|PDB:5EFQ}.
FT   HELIX       882    885       {ECO:0000244|PDB:5EFQ}.
FT   HELIX       894    908       {ECO:0000244|PDB:5EFQ}.
FT   STRAND      909    911       {ECO:0000244|PDB:5EFQ}.
FT   HELIX       919    930       {ECO:0000244|PDB:5EFQ}.
FT   TURN        935    937       {ECO:0000244|PDB:5EFQ}.
FT   HELIX       939    943       {ECO:0000244|PDB:5EFQ}.
FT   TURN        945    950       {ECO:0000244|PDB:5EFQ}.
FT   HELIX       960    963       {ECO:0000244|PDB:5EFQ}.
FT   TURN        964    966       {ECO:0000244|PDB:5EFQ}.
FT   HELIX       969    978       {ECO:0000244|PDB:5EFQ}.
FT   TURN        983    985       {ECO:0000244|PDB:5EFQ}.
FT   HELIX       989    994       {ECO:0000244|PDB:5EFQ}.
FT   TURN        996   1000       {ECO:0000244|PDB:5EFQ}.
FT   HELIX      1003   1005       {ECO:0000244|PDB:5EFQ}.
FT   HELIX      1019   1024       {ECO:0000244|PDB:5EFQ}.
FT   HELIX      1026   1030       {ECO:0000244|PDB:5EFQ}.
SQ   SEQUENCE   1512 AA;  164923 MW;  3CA54A3585A2943D CRC64;
     MPSSSDTALG GGGGLSWAEK KLEERRKRRR FLSPQQPPLL LPLLQPQLLQ PPPPPPPLLF
     LAAPGTAAAA AAAAAASSSC FSPGPPLEVK RLARGKRRAG GRQKRRRGPR AGQEAEKRRV
     FSLPQPQQDG GGGASSGGGV TPLVEYEDVS SQSEQGLLLG GASAATAATA AGGTGGSGGS
     PASSSGTQRR GEGSERRPRR DRRSSSGRSK ERHREHRRRD GQRGGSEASK SRSRHSHSGE
     ERAEVAKSGS SSSSGGRRKS ASATSSSSSS RKDRDSKAHR SRTKSSKEPP SAYKEPPKAY
     REDKTEPKAY RRRRSLSPLG GRDDSPVSHR ASQSLRSRKS PSPAGGGSSP YSRRLPRSPS
     PYSRRRSPSY SRHSSYERGG DVSPSPYSSS SWRRSRSPYS PVLRRSGKSR SRSPYSSRHS
     RSRSRHRLSR SRSRHSSISP STLTLKSSLA AELNKNKKAR AAEAARAAEA AKAAEATKAA
     EAAAKAAKAS NTSTPTKGNT ETSASASQTN HVKDVKKIKI EHAPSPSSGG TLKNDKAKTK
     PPLQVTKVEN NLIVDKATKK AVIVGKESKS AATKEESVSL KEKTKPLTPS IGAKEKEQHV
     ALVTSTLPPL PLPPMLPEDK EADSLRGNIS VKAVKKEVEK KLRCLLADLP LPPELPGGDD
     LSKSPEEKKT ATQLHSKRRP KICGPRYGET KEKDIDWGKR CVDKFDIIGI IGEGTYGQVY
     KARDKDTGEM VALKKVRLDN EKEGFPITAI REIKILRQLT HQSIINMKEI VTDKEDALDF
     KKDKGAFYLV FEYMDHDLMG LLESGLVHFN ENHIKSFMRQ LMEGLDYCHK KNFLHRDIKC
     SNILLNNRGQ IKLADFGLAR LYSSEESRPY TNKVITLWYR PPELLLGEER YTPAIDVWSC
     GCILGELFTK KPIFQANQEL AQLELISRIC GSPCPAVWPD VIKLPYFNTM KPKKQYRRKL
     REEFVFIPAA ALDLFDYMLA LDPSKRCTAE QALQCEFLRD VEPSKMPPPD LPLWQDCHEL
     WSKKRRRQKQ MGMTDDVSTI KAPRKDLSLG LDDSRTNTPQ GVLPSSQLKS QGSSNVAPVK
     TGPGQHLNHS ELAILLNLLQ SKTSVNMADF VQVLNIKVNS ETQQQLNKIN LPAGILATGE
     KQTDPSTPQQ ESSKPLGGIQ PSSQTIQPKV ETDAAQAAVQ SAFAVLLTQL IKAQQSKQKD
     VLLEERENGS GHEASLQLRP PPEPSTPVSG QDDLIQHQDM RILELTPEPD RPRILPPDQR
     PPEPPEPPPV TEEDLDYRTE NQHVPTTSSS LTDPHAGVKA ALLQLLAQHQ PQDDPKREGG
     IDYQAGDTYV STSDYKDNFG SSSFSSAPYV SNDGLGSSSA PPLERRSFIG NSDIQSLDNY
     STASSHSGGP PQPSAFSESF PSSVAGYGDI YLNAGPMLFS GDKDHRFEYS HGPIAVLANS
     SDPSTGPEST HPLPAKMHNY NYGGNLQENP SGPSLMHGQT WTSPAQGPGY SQGYRGHIST
     STGRGRGRGL PY
//
